MedBlog

New immunotherapy can prevent kidney cancer recurrence after surgery: Is it right for you?

The FDA has approved pembrolizumab immunotherapy, the first treatment to lower kidney cancer recurrence risk after surgery. UT Southwestern's Dr. Hans Hammers helps patients explore its benefits and risks.

Hans Hammers, M.D., Ph.D.

March 18, 2022

New immunotherapy drug combination is a significant advancement in kidney cancer therapy

A new immunotherapy drug combination has been dubbed a significant advancement in kidney cancer treatment. The combination of ipilimumab and nivolumab can improve outcomes and quality of life. Learn more.

Hans Hammers, M.D., Ph.D. / James Brugarolas, M.D., Ph.D.

December 17, 2018

The Team That's Doubling Cancer Survival Rates

Hans Hammers, M.D., Ph.D. / James Brugarolas, M.D., Ph.D.

November 9, 2018

Immunotherapy for kidney cancer: Using the body as a weapon

Kidney cancer patients may see long-lasting tumor shrinkage with immunotherapy, which uses the immune system as a weapon to fight cancer. Learn more.

Hans Hammers, M.D., Ph.D.

December 6, 2017